Page last updated: 2024-09-05

sorafenib and tyrosine

sorafenib has been researched along with tyrosine in 6 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(tyrosine)
Trials
(tyrosine)
Recent Studies (post-2010) (tyrosine)
6,5207305,25144,2738468,225

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW1
Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D1
Al-Salama, ZT; Scott, LJ; Syed, YY1
Christen, KE; Davis, RA; Kennedy, D1
Abu-Gharbieh, E; Abushawish, KYI; Al-Hroub, HM; Alzoubi, KH; Bustanji, Y; El-Huneidi, W; Elgendy, SM; Giddey, AD; Mousa, M; Omar, HA; Semreen, MH; Soares, NC; Soliman, SSM1
Duda, DG; Jain, RK1

Reviews

1 review(s) available for sorafenib and tyrosine

ArticleYear
Lenvatinib: A Review in Hepatocellular Carcinoma.
    Drugs, 2019, Volume: 79, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Treatment Outcome; Tyrosine

2019

Other Studies

5 other study(ies) available for sorafenib and tyrosine

ArticleYear
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine

2009
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:6

    Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing

2017
Psammaplysin F increases the efficacy of bortezomib and sorafenib through regulation of stress granule formation.
    The international journal of biochemistry & cell biology, 2019, Volume: 112

    Topics: Animals; Bortezomib; Chlorocebus aethiops; Cytoplasmic Granules; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Sorafenib; Spiro Compounds; Tyrosine; Vero Cells

2019
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
    International journal of molecular sciences, 2022, Oct-09, Volume: 23, Issue:19

    Topics: Alanine; Amino Acids; Antineoplastic Agents; Biomarkers; Calpain; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Folic Acid Antagonists; Glucose; Humans; L-Iditol 2-Dehydrogenase; Liver Neoplasms; Metabolic Networks and Pathways; Nucleotides; Phosphatidylcholines; Proline; Protein Kinase Inhibitors; Proteome; Proteomics; Sorafenib; Succinic Acid; Superoxide Dismutase; Tyrosine; Ubiquitin Thiolesterase; Uridine Diphosphate

2022
Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
    Cancer research, 2022, 10-17, Volume: 82, Issue:20

    Topics: Angiogenesis Inhibitors; Endothelial Cells; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Receptor Protein-Tyrosine Kinases; Sorafenib; Tyrosine

2022